Lantheus Holdings announced that the U.S. Food and Drug Administration has granted tentative approval for its Abbreviated New Drug Application for Lutetium‑Lu‑177 Dotatate (PNT2003). The approval, issued on March 2 2026, positions PNT2003 as a radio‑equivalent to the established therapy LUTATHERA® and marks a key regulatory milestone for the company’s expanding theranostic portfolio.
PNT2003 is a therapeutic agent designed for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). Lantheus licensed exclusive worldwide rights to the compound from POINT Biopharma Global, Inc. in December 2022; POINT Biopharma was acquired by Eli Lilly and Company in December 2023. The tentative approval is subject to a 30‑month stay that will expire in June 2026, after which full approval will be required for commercial launch.
In its most recent earnings release, Lantheus reported Q4 2025 worldwide revenue of $406.8 million, a 4.0 % increase from the same period in 2024, and adjusted fully diluted earnings per share of $1.67 versus $1.59 in the prior year. The earnings beat analyst expectations by $0.08 per share, driven by strong demand for its precision diagnostics products and disciplined cost management that offset declines in legacy product sales. The company’s Precision Diagnostics segment grew 22 % year‑over‑year, largely due to robust sales of DEFINITY and Neuraceq.
For 2026, Lantheus guided for revenue between $1.40 billion and $1.45 billion and adjusted fully diluted EPS between $5.00 and $5.25. These guidance figures are below the consensus estimates of $1.54 billion in revenue and $5.51 in EPS, reflecting management’s cautious outlook amid competitive pressures and the need to invest in the new therapeutic pipeline. The company’s CEO, Mary Anne Heino, noted that “In 2026 we are aligning our strategic focus on PET radiodiagnostics, with clear priorities around execution and investment.”
Market reaction to the announcement was muted, with investors focusing on the 2026 guidance rather than the tentative approval. The company’s stock experienced a negative pre‑market move, attributed to the lower revenue and earnings outlook that fell short of analyst consensus. The tentative approval, however, is viewed as a positive long‑term development that could broaden Lantheus’s revenue base once full approval is obtained.
The approval of PNT2003 signals Lantheus’s transition from a single‑product company to a fully integrated radiopharmaceutical platform. By adding a therapeutic candidate to its pipeline, the company diversifies its revenue streams and strengthens its competitive position in the growing neuroendocrine tumor market, where it competes with established players such as Novartis and Ipsen. The company’s strategic focus on PET radiodiagnostics and the development of radio‑equivalent therapies positions it to capture a larger share of the NET treatment landscape as the market expands.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.